公司資料
Freeline Therapeutics 股價、新聞與催化劑
- 股票代碼:
- FRLN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United Kingdom and traded in the U
股價為何變動
Current closing-price context is not available for FRLN.
公司概覽
業務概覽
Freeline Therapeutics was a gene-therapy company focused on treating serious diseases through AAV-based gene delivery. Its story centered on whether a gene-therapy platform could create durable value in rare disease.
所在地與產業分類
Freeline was headquartered in the United Kingdom and traded in the U.S. market. It sat in gene therapy and rare-disease biotechnology.
商業模式特徵
The company depended on clinical proof, manufacturing readiness, and capital efficiency in a tough gene-therapy environment. Investors watched data, safety, and strategic optionality.
生技產業定位
Freeline occupies a historical gene-therapy niche within biotech. It was highly sensitive to platform validation because the market needed evidence that the approach could scale.
未來催化劑
- Freeline is now a legacy / closeout story, with catalysts limited to any residual transaction or asset-resolution update. There is no active standalone pipeline story left.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。